Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease

NCT07843459 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07843459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07843459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Placebo-Controlled, Single- and Multiple-Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
July 31, 2028
Enrollment
111 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, amyloid, healthy volunteers, plaque, amyloid, plasma